Andrew Capacci, PhD
Dr. Capacci earned his undergraduate degree at the University of Toronto. His PhD work was completed at Princeton University in the lab of Dr. David MacMillan where he studied asymmetric organocatalysis and photoredox catalysis. In 2015, he joined Biogen where he worked on numerous drug discovery projects aimed at treating neurodegenerative diseases. He grew from individual contributor to program leader, supervising numerous chemists and leading project team members. He spearheaded efforts through hit validation, lead identification, and candidate selection activities. Dr. Capacci joined the IND in September 2023 as an Associate Adjunct Professor. He will leverage his synthetic and medicinal chemistry skills to assist in the discovery of small molecules that will solve unmet medical needs in the treatment of neurodegenerative diseases.